Cargando…
Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications
Microvascular complications characterized by retinopathy, nephropathy, and neuropathy are highly prevalent among diabetics. Glycemic control has long been the mainstay for preventing progression of these complications; however, such control is not easily achieved. Currently, alternative adjunctive a...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350125/ https://www.ncbi.nlm.nih.gov/pubmed/18200803 |
_version_ | 1782152852153565184 |
---|---|
author | Cumbie, Brian C Hermayer, Kathie L |
author_facet | Cumbie, Brian C Hermayer, Kathie L |
author_sort | Cumbie, Brian C |
collection | PubMed |
description | Microvascular complications characterized by retinopathy, nephropathy, and neuropathy are highly prevalent among diabetics. Glycemic control has long been the mainstay for preventing progression of these complications; however, such control is not easily achieved. Currently, alternative adjunctive approaches to treating and preventing microvascular damage are being undertaken by targeting the molecular pathogenesis of diabetic complications. This review summarizes the specific pathogenic mechanisms of microvascular complications for which clinical therapies have been developed, including the polyol pathway, advanced glycation end products, protein kinase c, vascular epithelium growth factor, and the superoxide pathway. The review further focuses on therapies for these targets that are currently available or are undergoing late-stage clinical trials. |
format | Text |
id | pubmed-2350125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-23501252008-05-08 Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications Cumbie, Brian C Hermayer, Kathie L Vasc Health Risk Manag Review Microvascular complications characterized by retinopathy, nephropathy, and neuropathy are highly prevalent among diabetics. Glycemic control has long been the mainstay for preventing progression of these complications; however, such control is not easily achieved. Currently, alternative adjunctive approaches to treating and preventing microvascular damage are being undertaken by targeting the molecular pathogenesis of diabetic complications. This review summarizes the specific pathogenic mechanisms of microvascular complications for which clinical therapies have been developed, including the polyol pathway, advanced glycation end products, protein kinase c, vascular epithelium growth factor, and the superoxide pathway. The review further focuses on therapies for these targets that are currently available or are undergoing late-stage clinical trials. Dove Medical Press 2007-12 /pmc/articles/PMC2350125/ /pubmed/18200803 Text en © 2007 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Cumbie, Brian C Hermayer, Kathie L Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications |
title | Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications |
title_full | Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications |
title_fullStr | Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications |
title_full_unstemmed | Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications |
title_short | Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications |
title_sort | current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350125/ https://www.ncbi.nlm.nih.gov/pubmed/18200803 |
work_keys_str_mv | AT cumbiebrianc currentconceptsintargetedtherapiesforthepathophysiologyofdiabeticmicrovascularcomplications AT hermayerkathiel currentconceptsintargetedtherapiesforthepathophysiologyofdiabeticmicrovascularcomplications |